Medigene Receives Chinese Patent for MDG1015 to Treat Various Solid Tumors
Shots:
- The Chinese Patent Office has issued a patent covering MDG1015 for the treatment of various solid tumors
- MDG1015 is being developed to treat solid tumors such as gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma. The company anticipates its IND submission & approval in Q3’24 with CTA filing & approval in Q4’24
- MDG1015, FIC third-gen. NY-ESO-1/LAGE-1a targeting TCR-T therapy, comprises an optimal affinity 3S NY-ESO-1/LAGE-1a TCR and PD1-41BB costimulatory switch protein to activate T cells through PD1/PD-L1 inhibition, improving its activity in tumor microenvironment
Ref: Medigene | Image: Medigene
Related News: BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
